Lipoprotein‐Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

Por Wallentin, Lars, Held, Claes, Armstrong, Paul W., Cannon, Christopher P., Davies, Richard Y., Granger, Christopher B., Hagström, Emil, Harrington, Robert A., Hochman, Judith S., Koenig, Wolfgang, Krug‐Gourley, Sue, Mohler, Emile R., Siegbahn, Agneta, Tarka, Elizabeth, Steg, Philippe Gabriel, Stewart, Ralph A. H., Weiss, Robert, Östlund, Ollie, White, Harvey D., Budaj, Andrzej, Ardissino, Diego, Avezum, Alvaro, Aylward, Philip E., Bryce, Alfonso, Chen, Hong, Chen, Ming‐Fong, Corbalan, Ramon, Dalby, Anthony J., Danchin, Nicolas, De Winter, Robbert J., Denchev, Stefan, Diaz, Rafael, Elisaf, Moses, Flather, Marcus D., Goudev, Assen R., Grinfeld, Liliana, Husted, Steen, Kim, Hyo‐Soo, Linhart, Ales, Lonn, Eva, López‐Sendón, José, Manolis, Athanasios J., Nicolau, José C., Pais, Prem, Parkhomenko, Alexander, Pedersen, Terje R., Pella, Daniel, Ramos‐Corrales, Marco A., Ruda, Mikhail, Sereg, Mátyás, Siddique, Saulat, Sinnaeve, Peter, Sritara, Piyamitr, Swart, Henk P., Sy, Rody G., Teramoto, Tamio, Tse, Hung‐Fat, Weaver, W. Douglas, Viigimaa, Margus, Vinereanu, Dragos, Zhu, Junren
Publicado no J Am Heart Assoc (2016)